No products in the cart.
Mouse Monoclonal Ret antibody [6E4C4] (STJ98359)
Supplier: St John’s Laboratory Ltd.
Recommended applications: WB, ELISA
Recommended dilution: WB 1:500-1:2000; ELISA 1:10000
Recommended protocols: check protocols
Click or hover above images to see image description for Ret Monoclonal Antibody.
Check alternative names for the antibodyExpand
RET antibody, CDHF12 antibody, CDHR16 antibody, PTC antibody, RET51 antibody,|C ret antibody|CDHF 12 antibody|CDHF12 antibody|CDHR16 antibody|ELKS Fusion gene antibody|HSCR 1 antibody|HSCR1 antibody|Hydroxyaryl protein kinase antibody|MEN2A antibody|MEN2B antibody|MTC 1 antibody|MTC1 antibody|Multiple endocrine neoplasia and medullary thyroid carcinoma 1 antibody|Oncogene RET antibody|Proto oncogene tyrosine protein kinase receptor ret antibody|Proto-oncogene c-Ret antibody|Proto-oncogene tyrosine-protein kinase receptor ret antibody|PTC antibody|RET antibody|RET ELE1 antibody|Ret Proto oncogene antibody|RET transforming sequence antibody|RET_HUMAN antibody|RET51 antibody|RET9 antibody|tyrosine-protein kinase receptor ret antibody|Anti-Ret antibody [EPR2871] (ab134100)
SCBT cat No: sc-20252|sc-23090|sc-23091|sc-23088|sc-85805|sc-86775|sc-165289|
Ret Monoclonal Antibody
|Catalogue No.|| |
Ret Monoclonal Antibody detects endogenous levels of Ret protein.
Purified recombinant fragment of Ret (aa896-1063) expressed in E Coli
|Recommended dilution|| |
WB 1:500-1:2000; ELISA 1:10000
Ret Antibody was tube-contained. Ascitic fluid containing 0.03% sodium azide.
Ret Antibody was purified using affinity purification.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
Proto-oncogene tyrosine-protein kinase receptor Ret antibody, Cadherin family member 12 antibody, Proto-oncogene c-Ret antibody
|Protein names|| |
Proto-oncogene tyrosine-protein kinase receptor Ret , Cadherin family member 12 , Proto-oncogene c-Ret
|Protein function|| |
Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer’s patch-like structures, a major component of the gut-associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e.g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration. / ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. / Repressed by 4-(3-hydroxyanilino)-quinolines derivatives, indolin-2-one-derivatives, 2-(alkylsulfanyl)-4-(3-thienyl) nicotinonitrile analogs, 3- and 4-substituted beta-carbolin-1-ones, vandetanib, motesanib, sorafenib (BAY 43-9006), cabozantinib (XL184), sunitinib, and withaferin A (WA). Inactivation by sorafenib both reduces kinase activity and promotes lysosomal degradation.
|Protein tissue specificity|| |
Positively regulated by NKX2-1, PHOX2B, SOX10 and PAX3.
|Involvement in disease|| |
Colorectal cancer (CRC) [MIM:114500]: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history. Note: The disease may be caused by mutations affecting the gene represented in this entry.; Hirschsprung disease 1 (HSCR1) [MIM:142623]: A disorder of neural crest development characterized by absence of enteric ganglia along a variable length of the intestine. It is the most common cause of congenital intestinal obstruction. Early symptoms range from complete acute neonatal obstruction, characterized by vomiting, abdominal distention and failure to pass stool, to chronic constipation in the older child. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Medullary thyroid carcinoma (MTC) [MIM:155240]: Rare tumor derived from the C cells of the thyroid. Three hereditary forms are known, that are transmitted in an autosomal dominant fashion: (a) multiple neoplasia type 2A (MEN2A), (b) multiple neoplasia type IIB (MEN2B) and (c) familial MTC (FMTC), which occurs in 25-30% of MTC cases and where MTC is the only clinical manifestation. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Multiple neoplasia 2B (MEN2B) [MIM:162300]: Uncommon inherited cancer syndrome characterized by predisposition to MTC and phaeochromocytoma which is associated with marfanoid habitus, mucosal neuromas, skeletal and ophthalmic abnormalities, and ganglioneuromas of the intestine tract. Then the disease progresses rapidly with the development of metastatic MTC and a pheochromocytome in 50% of cases. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Pheochromocytoma (PCC) [MIM:171300]: A catecholamine-producing tumor of chromaffin tissue of the adrenal medulla or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of epinephrine and norepinephrine, is hypertension, which may be persistent or intermittent. . Note: Disease susceptibility is associated with variations affecting the gene represented in this entry.; Multiple neoplasia 2A (MEN2A) [MIM:171400]: The most frequent form of medullary thyroid cancer (MTC). It is an inherited cancer syndrome characterized by MTC, phaeochromocytoma and/or hyperparathyroidism. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Note: Various chromosomal aberrations involving RET are known. Some of them have been found in papillary thyroid carcinomas (PTCs) (PubMed:12787916, PubMed:2406025, PubMed:10980597, PubMed:10439047). Inversion inv(10)(q11.2;q21) generates the RET/CCDC6 (PTC1) oncogene (PubMed:2406025). Inversion inv(10)(q11.2;q11.2) generates the RET/NCOA4 (PTC3) oncogene. Translocation t(10;14)(q11;q32) with GOLGA5 generates the RET/GOLGA5 (PTC5) oncogene (PubMed:2734021). Translocation t(8;10)(p21.3;q11.2) with PCM1 generates the PCM1/RET fusion (PubMed:10980597). Translocation t(6;10)(p21.3;q11.2) with TRIM27/RFP generates the Delta RFP/RET oncogene (PubMed:12787916). Translocation t(1;10)(p13;q11) with TRIM33 generates the TRIM33/RET (PTC7) oncogene (PubMed:10439047). Translocation t(7;10)(q32;q11) with TRIM24/TIF1 generates the TRIM24/RET (PTC6) oncogene (PubMed:10439047). Translocation t(6;10)(p21.3;q11.2) with TRIM27/RFP generates the TRIM27/RET oncogene (PubMed:3037315). .; Note: Mutations in RET have been detected in patients with renal agenesis suggesting a possible involvement of this gene in disease pathogenesis.; Congenital central hypoventilation syndrome (CCHS) [MIM:209880]: Rare disorder characterized by abnormal control of respiration in the absence of neuromuscular or lung disease, or an identifiable brain stem lesion. A deficiency in autonomic control of respiration results in inadequate or negligible ventilatory and arousal responses to hypercapnia and hypoxemia. . Note: The disease is caused by mutations affecting the gene represented in this entry.
|Protein sequence and domain|| |
Belongs to the protein kinase superfamily. Tyr protein kinase family. / Contains 1 cadherin domain. / Contains 1 protein kinase domain.
|Protein post-translational modifications|| |
Autophosphorylated on C-terminal tyrosine residues upon ligand stimulation. Dephosphorylated by PTPRJ on Tyr-905, Tyr-1015 and Tyr-1062. / Proteolytically cleaved by caspase-3. The soluble RET kinase fragment is able to induce cell death. The extracellular cell-membrane anchored RET cadherin fragment accelerates cell adhesion in sympathetic neurons.
|Protein cellular localization|| |
Cell membrane / Single-pass type I membrane protein / Endosome membrane / Single-pass type I membrane protein
AntibodyPlus can customize Ret Antibody according to your requirement, including bulk product size,etc. Please contact firstname.lastname@example.org. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: